Advanced Cell Technology, Mytogen Inc. deal

ACTC completed its previously announced acquisition of Mytogen for 8.2 million shares worth $2.2 million in stock based on ACTC's close of $0.27 on Sept. 19, the day before the deal closed (see BioCen...